Tirzepatide outperforms insulin in controlling diabetes and promoting weight loss in clinical trials
In a recent review and meta-analysis published in the International Journal of Obesity, researchers evaluated the safety and efficacy of once-weekly Tirzepatide, a revolutionary new anti-obesity and anti-diabetes drug, against conventional long- and ultra-long-acting insulin supplements in managing type 2 diabetes (T2D).